Novo Nordisk to end semaglutide kidney study early due to strong efficacy signals
Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...
top of page
Browse by category
Search
Study links GLP-1s with serious gastrointestinal conditions
Glucagon-like peptide-1 (GLP-1) agonists are associated with an increased risk of serious medical conditions including stomach paralysis,...
Rejuva GLP-1-based pancreatic gene therapy candidate results in greater weight loss vs. semaglutide
Fractyl Health has revealed preclinical findings from its Rejuva gene therapy platform at the European Association for the Study of...
Journal Watch 4/10/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Tirzepatide more effective in blood sugar control and body weight loss than semaglutide
A new meta-analysis combining 22 studies shows that tirzepatide is superior to semaglutide for both control of blood sugar and in terms...
Journal Watch 16/08/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
SELECT trial: Semaglutide reduces the risk of MACE by 20% in adults with overweight or obesity
Results from the SELECT cardiovascular outcomes trial has revealed that semaglutide 2.4mg demonstrated a statistically significant and...
EMA reviewing data after reports of suicidal thoughts and thoughts of self-harm after taking GLP-1a
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is reviewing data on the risk of suicidal...
Novo Nordisk to protect US patients from unlawful sales of non-FDA approved ‘semaglutide medicines’
Novo Nordisk is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and...
NHS England to prescribe semaglutide, potentially expanding access to tens of thousands of people
NHS doctors in England could soon be allowed to prescribe more people with Wegovy (semaglutide) under a new pilot scheme. It is hoped the...
Browse by tag
bottom of page